Analysis of the EphA2 Receptor Expression on Malignant Plasma
Cells and Plasmacytoid Dendritic Cells in MGUS and Multiple
Myeloma Patients

k 2016

Analysis of the EphA2 Receptor Expression on Malignant Plasma Cells and Plasmacytoid Dendritic Cells in MGUS and Multiple Myeloma Patients

KRCHNIAKOVÁ, Mária, Lucie RIHOVA, Romana KRÁLOVÁ, Rita PACASOVA, Miroslav PENKA et. al.

Základní údaje

Originální název

Analysis of the EphA2 Receptor Expression on Malignant Plasma Cells and Plasmacytoid Dendritic Cells in MGUS and Multiple Myeloma Patients

Autoři

KRCHNIAKOVÁ, Mária (703 Slovensko, domácí), Lucie RIHOVA (203 Česká republika), Romana KRÁLOVÁ (203 Česká republika, domácí), Rita PACASOVA (203 Česká republika), Miroslav PENKA (203 Česká republika), Zdenek ADAM (203 Česká republika), Ludek POUR (203 Česká republika), Roman HAJEK (203 Česká republika), Martin PISKÁČEK (40 Rakousko, domácí) a Andrea KNIGHT (203 Česká republika, garant, domácí)

Vydání

Gamma Delta Conference 2016, 2016

Další údaje

Jazyk

angličtina

Typ výsledku

Prezentace na konferencích

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Kód RIV

RIV/00216224:14110/16:00088872

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Multiple myeloma; MGUS; EphA2

Štítky

EL OK

Změněno: 16. 8. 2016 15:27, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Identification of ligands for human gamma-delta T cells remains a major challenge. The EphA2 (Ephrin receptor A2) has been identified as a ligand for the Vdelta1 gammadelta TCR transductants. The EphA2 is often over-expressed in aggressive cancers mainly of epithelial origin; however, the expression in haematological malignancies has not been determined. Multiple myeloma (MM) is a malignancy of plasma cells located in bone marrow with a premalignant stage MGUS (monoclonal gammopathy of undetermined significance). Plasmacytoid dendritic cells (pDC) are known to promote the tumour plasma cell growth, survival and drug resistance in myeloma. The aim was to determine the expression of EphA2 on myeloma plasma cells (PC) and pDCs (CD123+, CD303+, CD304+) using multicolour flow cytometry in MGUS and newly diagnosed MM patients. We have used bone marrow (BM) and paired peripheral blood (PB) samples from MGUS (n=6) and MM patients (n=11). The age-matched healthy donors were used as controls (BM n=9, PB n=16). In MGUS and MM patients, we found prominent EphA2 expression on tumour plasma cells in BM, while plasmablasts were mostly negative. PDC have been identified uniformly EphA2+ in both PB and BM in healthy donors and in MGUS and MM patients. In summary, we showed the expression of EphA2 receptor on myeloma cells correlating with malignant transformation. Since EphA2-positivity has been confirmed on pDC in MGUS and MM patients, we hypothesize that large expansions of Vdelta1 gammadelta T cells are driven by the interactions with pDC and PC expressing the EphA2 in the tumour microenvironment.

Návaznosti

NV15-32935A, projekt VaV

Název: Analýza gamma-delta T lymfocytů reaktivních na nádorové buňky u pacientů s B-buněčnou chronickou lymfocytární leukémií: nový přístup k buněčné terapii

3SGA5924, interní kód MU

Název: Investigations of human gamma-delta T cells: a new candidate for novel antiviral and antitumour immunotherapy (Akronym: Gammadelta T cells)

Investor: Jihomoravský kraj, Investigations of human gamma-delta T cells: a new candidate for novel antiviral and antitumour immunotherapy, Reintegrační granty

Citovat

KRCHNIAKOVÁ, Mária, Lucie RIHOVA, Romana KRÁLOVÁ, Rita PACASOVA, Miroslav PENKA, Zdenek ADAM, Ludek POUR, Roman HAJEK, Martin PISKÁČEK a Andrea KNIGHT. Analysis of the EphA2 Receptor Expression on Malignant Plasma Cells and Plasmacytoid Dendritic Cells in MGUS and Multiple Myeloma Patients. In Gamma Delta Conference 2016. 2016.

@proceedings{1351325,
   author = {Krchniaková, Mária and Rihova, Lucie and Králová, Romana and Pacasova, Rita and Penka, Miroslav and Adam, Zdenek and Pour, Ludek and Hajek, Roman and Piskáček, Martin and Knight, Andrea},
   booktitle = {Gamma Delta Conference 2016},
   keywords = {Multiple myeloma; MGUS; EphA2},
   language = {eng},
   title = {Analysis of the EphA2 Receptor Expression on Malignant Plasma Cells and Plasmacytoid Dendritic Cells in MGUS and Multiple Myeloma Patients},
   year = {2016}
}

TY  - CONF
ID  - 1351325
AU  - Krchniaková, Mária - Rihova, Lucie - Králová, Romana - Pacasova, Rita - Penka, Miroslav - Adam, Zdenek - Pour, Ludek - Hajek, Roman - Piskáček, Martin - Knight, Andrea
PY  - 2016
TI  - Analysis of the EphA2 Receptor Expression on Malignant Plasma Cells and Plasmacytoid Dendritic Cells in MGUS and Multiple Myeloma Patients
KW  - Multiple myeloma
KW  - MGUS
KW  - EphA2
N2  - Identification of ligands for human gamma-delta T cells remains a major challenge. The EphA2 (Ephrin receptor A2) has been identified as a ligand for the Vdelta1 gammadelta TCR transductants. The EphA2 is often over-expressed in aggressive cancers mainly of epithelial origin; however, the expression in haematological malignancies has not been determined. Multiple myeloma (MM) is a malignancy of plasma cells located in bone marrow with a premalignant stage MGUS (monoclonal gammopathy of undetermined significance). Plasmacytoid dendritic cells (pDC) are known to promote the tumour plasma cell growth, survival and drug resistance in myeloma. The aim was to determine the expression of EphA2 on myeloma plasma cells (PC) and pDCs (CD123+, CD303+, CD304+) using multicolour flow cytometry in MGUS and newly diagnosed MM patients. We have used bone marrow (BM) and paired peripheral blood (PB) samples from MGUS (n=6) and MM patients (n=11). The age-matched healthy donors were used as controls (BM n=9, PB n=16). In MGUS and MM patients, we found prominent EphA2 expression on tumour plasma cells in BM, while plasmablasts were mostly negative. PDC have been identified uniformly EphA2+ in both PB and BM in healthy donors and in MGUS and MM patients. In summary, we showed the expression of EphA2 receptor on myeloma cells correlating with malignant transformation. Since EphA2-positivity has been confirmed on pDC in MGUS and MM patients, we hypothesize that large expansions of Vdelta1 gammadelta T cells are driven by the interactions with pDC and PC expressing the EphA2 in the tumour microenvironment.
ER  -

Podrobný výpis o publikaci